Sanjiv Patel, Relay Therapeutics CEO
September 8, 2022 06:18 AM EDT
R&D

#ES­MO22: Re­lay Ther­a­peu­tics joins the win­ner's cir­cle this week­end as up­dat­ed can­cer da­ta win ap­plause

John Carroll

Editor & Founder

PARIS — Re­lay Ther­a­peu­tics had steadi­ly raised the bar ahead of ES­MO for RLY-4008, its bile duct can­cer drug for a nar­row group of pa­tients with …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

A service from the Financial Times